Home › Psoriasis › Texas › Houston
Psoriasis clinical trials in Houston, TX
3 studies for Psoriasis are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- UT MD Anderson Cancer Center, Houston
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RecruitingPhase 4
- Center for Clinical Studies, Houston
- Bellaire Dermatology Associates, Bellaire · 7 mi away
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RecruitingObservational study
- M D Anderson Cancer Center, Houston
About Psoriasis
Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. Some people also get psoriasis arthritis.
More about Psoriasis on MedlinePlus
Psoriasis trials in other cities
- Trenton, NJ7 studies
- Newton, MA6 studies
- Cleveland, OH6 studies
- Philadelphia, PA5 studies
- New York City, NY5 studies
- Fremont, CA5 studies
- San Antonio, TX5 studies
- Huntington Beach, CA4 studies
- Birmingham, AL4 studies
- San Diego, CA3 studies
- Rochester, NY3 studies
- Columbus, OH3 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)121 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia85 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer61 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.